Takeda’s Mobocertinib Approved in China for EGFR Exon20ins NSCLC
Japan-based Takeda Pharmaceutical Co., Ltd’s (TYO: 4502) China unit has announced receiving marketing approval from...
MediTrust Health Secures Series C+ Funding with HSBC as Strategic Investor
MediTrust Health, the insurance, financing, and direct-to-patient pharmacy subsidiary of China-based Shanghai Pharmaceuticals Holding Co.,...
Kelun-Biotech’s SKB264 Approved for Phase II Study in EGFR-Mutant NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the National Medical Products...
BeiGene Outlines Global R&D Strategy at J.P. Morgan Healthcare Summit
China-based biotech BeiGene (Nasdaq: BGNE, HKG: 6160) provided an update on its company strategy and...
Evopoint Biosciences Licenses SOS1 Inhibitor to METiS Therapeutics
China-based Evopoint Biosciences has announced a global licensing agreement with US firm METiS Therapeutics Inc.,...
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...
HKEX 2022 Annual Report: IPO Activity Declines Amid Global Challenges
The Hong Kong Exchanges and Clearing Ltd (HKEX) has released its annual report for 2022,...
Konruns Initiates Phase II Study for KC1036 in Advanced Thymic Tumors
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the initiation of a single-arm, open,...
Dizal’s Sunvozertinib NDA Accepted for Review by China’s NMPA
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...
HighTide Therapeutics Doses First Patient in Phase IIb Study for HTD1801 in NASH
Shenzhen-based HighTide Therapeutics Inc. has announced that the first patient has been dosed in a...
MSD Submits Initial Quotation for Molnupiravir in China Amid New COVID-19 Rules
Under new rules specifically for the launch of COVID-19 therapeutics in China, US-based Merck Sharp...
Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA
China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...
CDE Releases 66th Batch of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 66th batch of chemical generic reference...
Jiangsu Kanion’s KYS202002A Greenlit for Clinical Study in Multiple Myeloma
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving approval from the National...
Gaoling Medical Secures Funding for Infrared Thermotherapy Technology
Gaoling Medical, a Hangzhou-based developer of systemic infrared thermotherapy technology, has raised an undisclosed amount...
Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...
Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...
CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...
Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong
China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...
Innovent Biologics Doses First Patient in Phase III Study for Mazdutide
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...